Zobrazeno 1 - 10
of 25
pro vyhledávání: '"B. Nayl"'
Autor:
I. van Praagh, Catherine Abrial, Frédérique Penault-Llorca, Anne Cayre, Y-J Bignon, Nina Radosevic-Robin, Yannick Bidet, J.P. Jacquin, J-M Nabholtz, F Kwiatkoswki, A-V Bourcier, P. Chollet, N. Chalabi, F Del Piano, M.M. Dauplat, B. Nayl, V. Servent, Pascale Dubray-Longeras, M-A Mouret-Reynier, Nancy Uhrhammer
Publikováno v:
Cancer Research. 73:P1-08
Background: TNBC is a heterogenous group of tumors for some of which the Epithelial Growth Factor Receptor pathway (EGFR) may play an important role. We evaluated the efficacy and toxicity of an anti-EGFR antibody (cetuximab) combined with docetaxel,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7cd3feebc12f5d859a65a6111550c0c1
https://doi.org/10.1158/0008-5472.sabcs13-p1-08-34
https://doi.org/10.1158/0008-5472.sabcs13-p1-08-34
Autor:
Joseph Gligorov, Praagh-Doreau I Van, Nicole Tubiana-Mathieu, Christelle Jouannaud, M-A Mouret-Reynier, Frédérique Penault-Llorca, Laurence Vanlemmens, B. Nayl, Bettina Weber, F Mayer, H Devaud, Pascale Dubray-Longeras, J. P. Ferriere, Eloise Planchat, Thierry Petit, N. Chalabi, Fabrice Kwiatkowski, J-M Nabholtz, P. Chollet, Catherine Abrial, Olivier Tredan
Publikováno v:
Cancer Research. 71:P3-14
Background: Panitumumab is an antibody targeting the epidermal growth factor receptor (EGFR) to which a role has been suggested in TNBC. Consequently, we evaluated the combination of a standard chemotherapy (FEC 100 followed by T) with panitumumab as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f25b5d2b5ddf626dbcf079ef5e8e5800
https://doi.org/10.1158/0008-5472.sabcs11-p3-14-01
https://doi.org/10.1158/0008-5472.sabcs11-p3-14-01
Publikováno v:
Bulletin du Cancer. 96:1225-1232
For several years, research for treatment of advanced ovarian cancer in first line or in relapse was made on the basis of two concepts. The first one is to improve the response rate by increasing the dose of chemotherapy delivered by high dose chemot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c63d9069cb655cb0d1bd42b0d7b711ae
https://doi.org/10.1684/bdc.2009.1004
https://doi.org/10.1684/bdc.2009.1004
Publikováno v:
Oncologie. 8:152-159
La chimiosensibilite du cancer de l’ovaire est reconnue depuis plus de 30 ans. Pourtant, cette pathologie n’est chimiocurable que dans de tres faibles proportions aux stades evolues. C’est pourquoi plusieurs strategies ont ete envisagees pour c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6f4c31699986e0808eb999365c4b27e
https://doi.org/10.1007/s10269-006-0344-z
https://doi.org/10.1007/s10269-006-0344-z
Publikováno v:
Bulletin du cancer. 96(12)
For several years, research for treatment of advanced ovarian cancer in first line or in relapse was made on the basis of two concepts. The first one is to improve the response rate by increasing the dose of chemotherapy delivered by high dose chemot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3cf4352b9358444dd69c73a78a24a0f9
https://pubmed.ncbi.nlm.nih.gov/19939780
https://pubmed.ncbi.nlm.nih.gov/19939780
Autor:
Isabelle Van Praag, B. Nayl, Xavier Durando, Jean-Pierre Ferriere, Jean-Marc Nabholtz, Philippe Chollet, Marie-Ange Mouret-Reynier
Publikováno v:
Indian journal of surgical oncology. 1(1)
Tamoxifen has been considered for several decades as the standard upfront hormonal therapy for patients with endocrine-sensitive early breast cancer. The efficacy and favorable toxicity profiles of third-generation aromatase inhibitors (AIs), anastro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e11135724906821693243b8474380416
https://pubmed.ncbi.nlm.nih.gov/22930614
https://pubmed.ncbi.nlm.nih.gov/22930614
Autor:
S.A. Brahmi, C. Abrial, P. Dubray, P. Chollet, Jean-Marc Nabholtz, B. Nayl, Inès Raoelfils, Marie-Ange Mouret-Reynier, Frédérique Penault-Llorca, I. Van Praag
Publikováno v:
European Journal of Cancer. 47:S345-S346
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10e2940023dfd77c7455f1a269b66f57
https://doi.org/10.1016/s0959-8049(11)71494-0
https://doi.org/10.1016/s0959-8049(11)71494-0
Autor:
Nina Radosevic-Robin, Philippe Chollet, Jean-Philippe Jacquin, Marie-Mélanie Dauplat, Nancy Uhrhammer, Francesco Del Piano, Anne Cayre, Isabelle Van-Praagh, Nassera Chalabi, Anne-Véronique Bourcier, B. Nayl, Pascale Dubray-Longeras, Yves-Jean Bignon, V. Servent, Fabrice Kwiatkowski, Catherine Abrial, Yannick Bidet, Marie-Ange Mouret-Reynier, Frédérique Penault-Llorca, Jean-Marc Nabholtz
Publikováno v:
Journal of Clinical Oncology. 31:1057-1057
1057 Background: Cetuximab is an antiboby targeting the epidermal growth factor receptor (EGFR) to which a role has been suggested in TNBC. Therefore, we evaluated the combination of docetaxel with cetuximab as neoadjuvant therapy of operable TNBC. M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f659ac2156fa230c7967cfc0f5b7c8b0
https://doi.org/10.1200/jco.2013.31.15_suppl.1057
https://doi.org/10.1200/jco.2013.31.15_suppl.1057
Autor:
Hervé Devaud, C. Pomel, Xavier Durando, M.-A. Mouret-Reynier, A.F. Dillies, Catherine Abrial, B. Nayl, Emilie Thivat, P. Chollet, Pascale Dubray-Longeras, Hervé Curé, Jean-Marc Nabholtz, Eloise Planchat, Qian Wang-Lopez
Publikováno v:
Journal of Clinical Oncology. 29:1121-1121
1121 Background: Metastatic breast cancer (MBC) is an incurable disease in most cases; then treatment is palliative, to prolong overall survival (OS) and control clinical symptoms. Progressively the figures obtained have improved with time. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::23840b69f2ba523f3dc048ea35981fe2
https://doi.org/10.1200/jco.2011.29.15_suppl.1121
https://doi.org/10.1200/jco.2011.29.15_suppl.1121
Autor:
Jean-Marc Nabholtz, M.-A. Mouret-Reynier, Bettina Weber, Nicole Tubiana-Mathieu, Laurence Vanlemmens, Frédérique Penault-Llorca, Nassera Chalabi, Hervé Devaud, Christelle Jouannaud, Thierry Petit, Pascale Dubray-Longeras, P. Chollet, Joseph Gligorov, I. Van Praagh-Doreau, Bruno Coudert, Catherine Abrial, Olivier Tredan, B. Nayl, Eloise Planchat, J. P. Ferriere
Publikováno v:
Journal of Clinical Oncology. 29:e11574-e11574
e11574 Background: Panitumumab is an antiboby targeting the epidermal growth factor receptor (EGFR) to which a role has been suggested in TNBC. Consequently, we evaluated the combination of a standard chemotherapy (FEC100 followed by T) with panitumu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dfe03ae6c35b7c3f764914a6f8f6daab
https://doi.org/10.1200/jco.2011.29.15_suppl.e11574
https://doi.org/10.1200/jco.2011.29.15_suppl.e11574